The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination
Launched by ROYAN INSTITUTE · Oct 9, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
The proposal of This study approved by our institutional review boards and institution's ethical committee, and all Participants will sign a written consent before enter to study. All patients will be randomly divided into two groups, A and B. Stimulation will begin on day 3 with the administration of 100 mg of clomifen citrate(CC) daily for 5 days. On day 8, ethinyl estradiol will be given daily for 5 days in group A and placebo will be given for 5 days in group B. Plasma levels of estradiol(E2), Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH) will be evaluated on days 3 an...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • The patients with first treatment cycle
- • Age between 25 and 30 years,
- • Infertility for at least 2 years' duration,
- • Oligomenorrhea or amenorrhea associated with a positive Progesterone challenge test
- • Women with normal concentrations of prolactin, free thyroxin and thyroid-stimulating hormone (TSH)
- Exclusion Criteria:
- • Women whose partners had an abnormal semen analysis according to World Health Organization
- • Women who had uterine or tubal abnormalities on hysterosalpingography, and women who had a body mass index of \>30 kg/m2.
About Royan Institute
The Royan Institute is a leading research organization dedicated to advancing the fields of reproductive health, stem cell biology, and regenerative medicine. Established to promote scientific innovation and clinical applications, the Institute focuses on translating cutting-edge research into therapeutic solutions. With a strong commitment to ethical practices and collaboration, Royan Institute conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices globally. Through its multidisciplinary approach and state-of-the-art facilities, the Institute strives to push the boundaries of medical science and contribute significantly to the understanding and treatment of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
hamid gourabi, PhD
Study Chair
President of Royan Institute
Ashraf Moieni, MD
Study Director
Scientific Board
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials